Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: Preclinical mechanistic studies

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1756-1764

  Reddy, N ^a,b   Czuczman, M S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Bortezomib; Chemoresistance; Hematologic malignancies; Nuclear factor (NF) B; Proteasome

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BELINOSTAT; BORTEZOMIB; BUTYRIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETHONAFIDE; ETOPOSIDE; LENALIDOMIDE; LONAFARNIB; LY 2228820; MELPHALAN; OBATOCLAX; OBLIMERSEN; PANOBINOSTAT; PERIFOSINE; PROTEASOME; RITUXIMAB; ROMIDEPSIN; SCIO 469; TANESPIMYCIN; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIZATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENTIATION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELOMA CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 77956108780     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq009     Document Type: Review

References (53)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
2. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 2006; 119: 971-979.
3. Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99: 14374-14379.
4. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418-5424.
5. Gu H, Chen X, Gao G et al. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7: 2298-2307.
6. Yanamandra N, Colaco NM, Parquet NA et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006; 12: 591-599.
7. Bianchi G, Oliva L, Cascio P et al. Proteasome stress causes apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2008; 112(11): (Abstr 247).
8. Kukreja A, Hutchinson A, Mazumder A et al. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br J Haematol 2007; 136: 106-110.
9. Ma MH, Yang HH, Parker K et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
10. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
11. Roccaro AM, Hideshima T, Raje N et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-191.
12. Hideshima T, Mitsiades C, Akiyama M et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
13. Hideshima T, Ikeda H, Chauhan D et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046-1052.
14. Strauss SJ, Higginbottom K, Juliger S et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007; 67: 2783-2790.
15. Pham LV, Tamayo AT, Yoshimura LC et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
16. Perez-Galan P, Roue G, Villamor N et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257-264.
17. Kabore AF, Sun J, Hu X et al. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175-1193.
18. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530.
19. Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
20. Catley L, Weisberg E, Kiziltepe T et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
21. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839-3852.
22. Feng R, Oton A, Mapara MY et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-397.
23. David E, Sun SY, Waller EK et al. The combination of the farnesyl transferase inhibitor (lonafarnib) and the proteasome inhibitor (bortezomib) induces synergistic apoptosis in human myeloma cells that is associated with downregulation of p-AKT. Blood 2005; 106: 4322-4329.
24. Kaufman JL, David E, Torre C et al. Enhanced levels of apoptosis by combination of farnesyl transferase inhibition (tipifarnib) and proteasome inhibition (bortezomib) in myeloma cell lines and primary myeloma cells and its mechanistic effects on Akt and caspase pathways. Blood 2005; 106(11): 451a (Abstr).
25. Navas TA, Nguyen AN, Hideshima T et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20: 1017-1027.
26. Ishitsuka K, Hideshima T, Neri P et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008; 141: 598-606.
27. Congdon LM, Pourpak A, Escalante AM et al. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol 2008; 75: 883-890.
28. Chauhan D, Velankar M, Brahmandam M et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374-2380.
29. Hideshima T, Catley L, Raje N et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007; 138: 783-791.
30. Hideshima T, Bradner JE, Wong J et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102: 8567-8572.
31. Weigert O, Pastore A, Rieken M et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21: 524-528.
32. Wadehra N, Lin T, Ryan T et al. Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. Blood 2005; 106(11): 677a (Abstr).
33. Wang M, Han XH, Zhang L et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008; 22: 179-185.
34. Heider U, von MI, Kaiser M et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133-142.
35. Rao R, Fiskus W, Yang Y et al. Co-treatment with panobinostat enhances bortezomib-induced unfolded protein response, endoplasmic reticulum stress and apoptosis of human mantle cell lymphoma cells. Blood 2008; 112(11): (Abstr 887).
36. Dai Y, Chen S, Kramer LB et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008; 14: 549-558.
37. O'Connor OA, Smith EA, Toner LE et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006; 12: 2902-2911.
38. Gruber EA, Czuczman MS, Olejniczak SH et al. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood 2007; 110(11): 417a (Abstr).
39. Perez-Galan P, Roue G, Villamor N et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441-4449.
40. Dasmahapatra G, Lembersky D, Rahmani M et al. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther 2009; 8: 808-819.
41. Leleu X, Eeckhoute J, Jia X et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia. Blood 2008; 111: 5068-5077.
42. Moreau AS, Jia X, Ngo HT et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-4972.
43. Chauhan D, Li G, Auclair D et al. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 2004; 9: 149-155.
44. Chauhan D, Li G, Hideshima T et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102: 3379-3386.
45. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008; 14: 1550-1560.
46. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270-1281.
47. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076.
48. Chauhan D, Li G, Shringarpure R et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63: 6174-6177.
49. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-1100.
50. Voorhees PM, Chen Q, Kuhn DJ et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478.
51. Markovina S, Callander NS, O'Connor SL et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356-1364.
52. Yang DT, Young KH, Kahl BS et al. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008; 7: 40.
53. Richardson PG, Mitsiades C, Ghobrial I et al. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006; 18: 598-608.